BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hwangbo H, Kim MY, Ji SY, Kim SY, Lee H, Kim GY, Park C, Keum YS, Hong SH, Cheong J, Choi YH. Auranofin Attenuates Non-Alcoholic Fatty Liver Disease by Suppressing Lipid Accumulation and NLRP3 Inflammasome-Mediated Hepatic Inflammation In Vivo and In Vitro. Antioxidants (Basel) 2020;9:E1040. [PMID: 33114221 DOI: 10.3390/antiox9111040] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Lu H, Lu W, Zhu Y, Wang C, Shi L, Li X, Wu Z, Wang G, Dong W, Tan C, Liu M. Auranofin Has Advantages over First-Line Drugs in the Treatment of Severe Streptococcus suis Infections. Antibiotics (Basel) 2020;10:26. [PMID: 33396878 DOI: 10.3390/antibiotics10010026] [Reference Citation Analysis]
2 Luo M, Ma X, Jiang W, Zhang J, Liu W, Wei S, Liu H. Novel phosphanegold(I) thiolate complexes suppress de novo lipid synthesis in human lung cancer. European Journal of Medicinal Chemistry 2022. [DOI: 10.1016/j.ejmech.2022.114168] [Reference Citation Analysis]
3 Bignold R, Johnson JR. Effects of cytokine signaling inhibition on inflammation-driven tissue remodeling. Curr Res Pharmacol Drug Discov 2021;2:100023. [PMID: 34909658 DOI: 10.1016/j.crphar.2021.100023] [Reference Citation Analysis]
4 Wang M, Wang K, Liao X, Hu H, Chen L, Meng L, Gao W, Li Q. Carnitine Palmitoyltransferase System: A New Target for Anti-Inflammatory and Anticancer Therapy? Front Pharmacol 2021;12:760581. [PMID: 34764874 DOI: 10.3389/fphar.2021.760581] [Reference Citation Analysis]
5 Dabravolski SA, Bezsonov EE, Baig MS, Popkova TV, Nedosugova LV, Starodubova AV, Orekhov AN. Mitochondrial Mutations and Genetic Factors Determining NAFLD Risk. Int J Mol Sci 2021;22:4459. [PMID: 33923295 DOI: 10.3390/ijms22094459] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]